Summary Oral anticoagulant therapy (OAT) is used to prevent and treat thromboembolic diseases. The new oral anticoagulants (NOAs) can be prescribed at fixed dosage without adjustment by laboratory testing. However, this does not necessarily mean that the laboratory does not play a role for their management. This position paper represents the consensus document of three Italian scientific societies dealing with laboratory issues in thrombosis and haemostasis. It is aimed at reviewing (i) which test(s) should be used to evaluate the anticoagulant effect of each of the NOAs presently available (i.e., dabigatran, rivaroxaban and apixaban); (ii) the patients to be investigated and (iii) the timing of investigation.
|Translated title of the contribution||Consensus document of FCSA, SIMeL, SIBioC e CISMEL on laboratory monitoring of novel oral anticoagulant drugs|
|Number of pages||3|
|Journal||Rivista Italiana della Medicina di Laboratorio|
|Publication status||Published - Sep 2013|
ASJC Scopus subject areas
- Biochemistry, medical
- Medical Laboratory Technology